FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079207870> ?p ?o ?g. }

• W2079207870 endingPage "6384" @default.
• W2079207870 startingPage "6381" @default.
• W2079207870 abstract "From a HTS campaign, a new series of pyrimidone anilides exemplified by compound 1 has been identified with good inhibitory activity for the PI3Kβ isoform. The structure of compound 1 in PI3Kγ was solved revealing a binding mode in agreement with the SAR observed on PI3Kβ. These compounds displayed inhibition in the nanomolar range in the biochemical assay and were also potent p-Akt inhibitors in a PTEN-deficient PC3 prostate cancer cell line. Optimization of in vitro pharmocokinetic properties led to compound 25 exhibiting 52% bioavailability in mice and target engagement in an acute PK/PD study." @default.
• W2079207870 created "2016-06-24" @default.
• W2079207870 creator A5003144687 @default.
• W2079207870 creator A5005153959 @default.
• W2079207870 creator A5011668840 @default.
• W2079207870 creator A5014979493 @default.
• W2079207870 creator A5015626556 @default.
• W2079207870 creator A5018499235 @default.
• W2079207870 creator A5020235332 @default.
• W2079207870 creator A5024944117 @default.
• W2079207870 creator A5032265961 @default.
• W2079207870 creator A5034583388 @default.
• W2079207870 creator A5044650603 @default.
• W2079207870 creator A5045635957 @default.
• W2079207870 creator A5047363846 @default.
• W2079207870 creator A5049199255 @default.
• W2079207870 creator A5049495232 @default.
• W2079207870 creator A5050221240 @default.
• W2079207870 creator A5052438850 @default.
• W2079207870 creator A5059310331 @default.
• W2079207870 creator A5060009480 @default.
• W2079207870 creator A5077555140 @default.
• W2079207870 creator A5079467950 @default.
• W2079207870 creator A5087016791 @default.
• W2079207870 creator A5091893544 @default.
• W2079207870 date "2012-10-01" @default.
• W2079207870 modified "2023-10-17" @default.
• W2079207870 title "Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors" @default.
• W2079207870 cites W1991740243 @default.
• W2079207870 cites W1993240342 @default.
• W2079207870 cites W2008525757 @default.
• W2079207870 cites W2015177518 @default.
• W2079207870 cites W2087693130 @default.
• W2079207870 cites W2093794547 @default.
• W2079207870 cites W2097559461 @default.
• W2079207870 cites W2124593509 @default.
• W2079207870 cites W2127355894 @default.
• W2079207870 cites W2165045529 @default.
• W2079207870 cites W2167009545 @default.
• W2079207870 cites W2316663096 @default.
• W2079207870 doi "https://doi.org/10.1016/j.bmcl.2012.08.072" @default.
• W2079207870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22981333" @default.
• W2079207870 hasPublicationYear "2012" @default.
• W2079207870 type Work @default.
• W2079207870 sameAs 2079207870 @default.
• W2079207870 citedByCount "18" @default.
• W2079207870 countsByYear W20792078702012 @default.
• W2079207870 countsByYear W20792078702013 @default.
• W2079207870 countsByYear W20792078702014 @default.
• W2079207870 countsByYear W20792078702015 @default.
• W2079207870 countsByYear W20792078702016 @default.
• W2079207870 countsByYear W20792078702017 @default.
• W2079207870 countsByYear W20792078702019 @default.
• W2079207870 countsByYear W20792078702020 @default.
• W2079207870 countsByYear W20792078702023 @default.
• W2079207870 crossrefType "journal-article" @default.
• W2079207870 hasAuthorship W2079207870A5003144687 @default.
• W2079207870 hasAuthorship W2079207870A5005153959 @default.
• W2079207870 hasAuthorship W2079207870A5011668840 @default.
• W2079207870 hasAuthorship W2079207870A5014979493 @default.
• W2079207870 hasAuthorship W2079207870A5015626556 @default.
• W2079207870 hasAuthorship W2079207870A5018499235 @default.
• W2079207870 hasAuthorship W2079207870A5020235332 @default.
• W2079207870 hasAuthorship W2079207870A5024944117 @default.
• W2079207870 hasAuthorship W2079207870A5032265961 @default.
• W2079207870 hasAuthorship W2079207870A5034583388 @default.
• W2079207870 hasAuthorship W2079207870A5044650603 @default.
• W2079207870 hasAuthorship W2079207870A5045635957 @default.
• W2079207870 hasAuthorship W2079207870A5047363846 @default.
• W2079207870 hasAuthorship W2079207870A5049199255 @default.
• W2079207870 hasAuthorship W2079207870A5049495232 @default.
• W2079207870 hasAuthorship W2079207870A5050221240 @default.
• W2079207870 hasAuthorship W2079207870A5052438850 @default.
• W2079207870 hasAuthorship W2079207870A5059310331 @default.
• W2079207870 hasAuthorship W2079207870A5060009480 @default.
• W2079207870 hasAuthorship W2079207870A5077555140 @default.
• W2079207870 hasAuthorship W2079207870A5079467950 @default.
• W2079207870 hasAuthorship W2079207870A5087016791 @default.
• W2079207870 hasAuthorship W2079207870A5091893544 @default.
• W2079207870 hasConcept C104317684 @default.
• W2079207870 hasConcept C121608353 @default.
• W2079207870 hasConcept C126322002 @default.
• W2079207870 hasConcept C181389837 @default.
• W2079207870 hasConcept C185592680 @default.
• W2079207870 hasConcept C190283241 @default.
• W2079207870 hasConcept C193042331 @default.
• W2079207870 hasConcept C202751555 @default.
• W2079207870 hasConcept C21951064 @default.
• W2079207870 hasConcept C2777609662 @default.
• W2079207870 hasConcept C2778439535 @default.
• W2079207870 hasConcept C2780192828 @default.
• W2079207870 hasConcept C53345823 @default.
• W2079207870 hasConcept C55493867 @default.
• W2079207870 hasConcept C71240020 @default.
• W2079207870 hasConcept C71924100 @default.
• W2079207870 hasConcept C86554907 @default.
• W2079207870 hasConcept C98274493 @default.
• W2079207870 hasConceptScore W2079207870C104317684 @default.

• next